Completed PHASE1 INTERVENTIONAL 1-arm NCT02438215

Study of IRX4204 for Treatment of Early Parkinson's Disease

An Open-Label, Single Site Study Using [123I]β-CIT Single Photon Emission Tomography (SPECT) to Evaluate Dopamine Transporter Binding Following Treatment With IRX4204 in Early Parkinson's Disease Subjects

Sponsor: Io Therapeutics

Conditions Parkinson's Disease

Interventions IRX4204

Updated 6 times since 2017 Last updated: May 7, 2015 Started: Aug 31, 2014 Primary completion: May 31, 2015 Completion: May 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Parkinson's Disease, this trial is completed. The trial is conducted by Io Therapeutics and has accumulated 6 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Aug 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Io Therapeutics

Data source: Io Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New Haven, United States